Results 221 to 230 of about 43,637 (267)

Enhancing CYP3A4 Inhibition Prediction Using a Hybrid GNN-ML Model with Data Augmentation. [PDF]

Pharmaceuticals (Basel)
Woo S, Jeon JH, Han S, Lee C, Min SH.
europepmc   +1 more source

Pharmacokinetics of Dexamethasone in Tuberculous Meningitis. [PDF]

Clin Infect Dis
Calderin JM, Resendiz-Galvan JE, Abdelgawad N, Davis A, Stek C, Wiesner L, Meintjes G, Wilkinson RJ, Denti P, Wasserman S.   +9 more
europepmc   +1 more source

Coenzyme Q10 protects against atorvastatin-induced hepatotoxicity via attenuation of oxidative stress and functional modulation of CYP3A1. [PDF]

BMC Pharmacol Toxicol
Abdel-Rasol MA, Anwar MS, Taha HA, El-Sayed WM, AbdelRaouf K.   +4 more
europepmc   +1 more source

Integrated network toxicology suggests potential mechanisms involving environmental flame retardant TDCPP in ovarian cancer progression via "liver-to-ovary crosstalk." [PDF]

Environ Health
Shi Z, Li Z, Li Y, Yang F.
europepmc   +1 more source

Evaluation of Drug-Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants. [PDF]

Clin Transl Sci
Luckey A, Larson KB, Rayad N, Heep M, Delhomme S, Kornmann G, Mueller JP, O'Donnell JP, O'Brien S, Fuhr R, Gillon JY.   +10 more
europepmc   +1 more source

A Clinically Relevant Drug Interaction Between Busulfan and Rifampin in the Setting of Hematopoietic Stem Cell Transplant Conditioning. [PDF]

Pharmacol Res Perspect
Drangines C, Laquet J, Kunwor R.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Effect of Mibefradil on CYP3A4 In Vivo

The Journal of Clinical Pharmacology, 2003
Mibefradil, a calcium channel blocker, was removed from the market because of adverse drug interactions with coadministered CYP3A4 substrates. This study examined the effect of mibefradil on the activity of hepatic and intestinal CYP3A4 in vivo, employing the erythromycin breath test (EBT) and oral midazolam pharmacokinetics.
Maria L, Veronese, Lisa P, Gillen, Ellen P, Dorval, Walter W, Hauck, Scott A, Waldman, Howard E, Greenberg   +5 more
openaire   +2 more sources

Pioglitazone: Effect on CYP3A4 Activity

The Journal of Clinical Pharmacology, 2002
Clinical studies demonstrate CYP3A4 enzyme induction with troglitazone, a thiazolidinedione derivative structurally related to pioglitazone. The objective of this prospective, open‐label study conducted in healthy volunteers was to evaluate the influence of multiple‐dose pioglitazone therapy on the urinary excretion ratio of 6‐β‐hydroxycortisol to ...
Sandra N, Nowak, David J, Edwards, Anthony, Clarke, Gail D, Anderson, Linda A, Jaber   +4 more
openaire   +2 more sources

Metabolic Activation of Benzodiazepines by CYP3A4

Drug Metabolism and Disposition, 2009
Cytochrome P450 3A4 is the predominant isoform in liver, and it metabolizes more than 50% of the clinical drugs commonly used. However, CYP3A4 is also responsible for metabolic activation of drugs, leading to liver injury. Benzodiazepines are widely used as hypnotics and sedatives for anxiety, but some of them induce liver injury in humans.
Katsuhiko, Mizuno, Miki, Katoh, Hirotoshi, Okumura, Nao, Nakagawa, Toru, Negishi, Takanori, Hashizume, Miki, Nakajima, Tsuyoshi, Yokoi   +7 more
openaire   +2 more sources

CYP3A4: The Workhorse

2015
This chapter discusses the genetics, metabolic actions, substrates, inducers, and inhibitors of cytochrome P450 3A4.
Jennifer DeCou, Nathaniel Birgenheier, Randal O. Dull   +2 more
openaire   +1 more source